261 related articles for article (PubMed ID: 22069361)
1. Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients.
Tzani P; Crisafulli E; Nicolini G; Aiello M; Chetta A; Clini EM; Olivieri D
Int J Chron Obstruct Pulmon Dis; 2011; 6():503-9. PubMed ID: 22069361
[TBL] [Abstract][Full Text] [Related]
2. The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging.
De Backer J; Vos W; Vinchurkar S; Van Holsbeke C; Poli G; Claes R; Salgado R; De Backer W
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):88-99. PubMed ID: 25004168
[TBL] [Abstract][Full Text] [Related]
3. Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD.
Singh D; Nicolini G; Bindi E; Corradi M; Guastalla D; Kampschulte J; Pierzchała W; Sayiner A; Szilasi M; Terzano C; Vestbo J;
BMC Pulm Med; 2014 Mar; 14():43. PubMed ID: 24621109
[TBL] [Abstract][Full Text] [Related]
4. The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD.
Dean J; Panainte C; Khan N; Singh D
Respir Res; 2020 Dec; 21(1):323. PubMed ID: 33298062
[TBL] [Abstract][Full Text] [Related]
5. Fluticasone propionate/formoterol for COPD management: a randomized controlled trial.
Papi A; Dokic D; Tzimas W; Mészáros I; Olech-Cudzik A; Koroknai Z; McAulay K; Mersmann S; Dalvi PS; Overend T
Int J Chron Obstruct Pulmon Dis; 2017; 12():1961-1971. PubMed ID: 28740376
[TBL] [Abstract][Full Text] [Related]
6. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
Cazzola M; Santus P; Di Marco F; Boveri B; Castagna F; Carlucci P; Matera MG; Centanni S
Respir Med; 2003 May; 97(5):453-7. PubMed ID: 12735659
[TBL] [Abstract][Full Text] [Related]
7. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K
Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and tolerability of beclomethasone/formoterol and fluticasone/salmeterol fixed combination in Taiwanese asthmatic patients.
Hsieh MJ; Lin YC; Lai RS; Wu CL; Lai CL; Wang CC; Perng DW; Kao SJ; Chang ET; Wang HC; Perng WC; Hsu JY; Lin CH; Tsai YH
J Formos Med Assoc; 2018 Dec; 117(12):1078-1085. PubMed ID: 29292054
[TBL] [Abstract][Full Text] [Related]
9. Stepping-across controlled asthmatic patients to extrafine beclometasone/formoterol combination.
Barnes N; van Noord JA; Brindicci C; Lindemann L; Varoli G; Perpiña M; Guastalla D; Casula D; Patel S; Chanez P;
Pulm Pharmacol Ther; 2013 Oct; 26(5):555-61. PubMed ID: 23524015
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis.
Cope S; Kraemer M; Zhang J; Capkun-Niggli G; Jansen JP
Int J Chron Obstruct Pulmon Dis; 2012; 7():415-20. PubMed ID: 22848154
[TBL] [Abstract][Full Text] [Related]
11. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change.
Jones PW; Anderson JA; Calverley PM; Celli BR; Ferguson GT; Jenkins C; Yates JC; Vestbo J; Spencer MD;
Respir Res; 2011 May; 12(1):71. PubMed ID: 21627828
[TBL] [Abstract][Full Text] [Related]
12. Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium
Beaulieu J; Jensen D; O'Donnell DE; Brouillard C; Tracey L; Vincent S; Nadreau É; Bernard E; Bernard S; Maltais F
Ther Adv Respir Dis; 2020; 14():1753466620939507. PubMed ID: 32663102
[TBL] [Abstract][Full Text] [Related]
13. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma.
Gerzeli S; Rognoni C; Quaglini S; Cavallo MC; Cremonesi G; Papi A
Clin Drug Investig; 2012 Apr; 32(4):253-65. PubMed ID: 22352412
[TBL] [Abstract][Full Text] [Related]
15. Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma.
Scichilone N; Battaglia S; Sorino C; Paglino G; Martino L; Paternò A; Santagata R; Spatafora M; Nicolini G; Bellia V
Allergy; 2010 Jul; 65(7):897-902. PubMed ID: 20121764
[TBL] [Abstract][Full Text] [Related]
16. Real life clinical study design supporting the effectiveness of extra-fine inhaled beclomethasone/formoterol at the level of small airways of asthmatics.
Popov TA; Petrova D; Kralimarkova TZ; Ivanov Y; Popova T; Peneva M; Odzhakova T; Ilieva Y; Yakovliev P; Lazarova T; Georgiev O; Hodzhev V; Hodzheva E; Staevska MT; Dimitrov VD
Pulm Pharmacol Ther; 2013 Dec; 26(6):624-9. PubMed ID: 23769863
[TBL] [Abstract][Full Text] [Related]
17. A study to assess COPD Symptom-based Management and to Optimise treatment Strategy in Japan (COSMOS-J) based on GOLD 2011.
Betsuyaku T; Kato M; Fujimoto K; Hagan G; Kobayashi A; Hitosugi H; James M; Jones PW
Int J Chron Obstruct Pulmon Dis; 2013; 8():453-9. PubMed ID: 24124358
[TBL] [Abstract][Full Text] [Related]
18. Effect of fluticasone/salmeterol combination on dyspnea and respiratory mechanics in mild-to-moderate COPD.
Guenette JA; Webb KA; O'Donnell DE
Respir Med; 2013 May; 107(5):708-16. PubMed ID: 23421968
[TBL] [Abstract][Full Text] [Related]
19. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
[TBL] [Abstract][Full Text] [Related]
20. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
